Bevrixa-50 Tablets are a pharmaceutical antiepileptic formulation designed for advanced control of partial-onset seizures. Containing brivaracetam, the formulation provides rapid and targeted seizure control by stabilizing abnormal neuronal firing and preventing seizure spread. Its high brain penetration and strong synaptic vesicle protein binding make it an effective option for patients requiring reliable seizure management.
Bevrixa-50 Tablets are a pharmaceutical antiepileptic formulation designed for advanced control of partial-onset seizures. Containing brivaracetam, the formulation provides rapid and targeted seizure control by stabilizing abnormal neuronal firing and preventing seizure spread. Its high brain penetration and strong synaptic vesicle protein binding make it an effective option for patients requiring reliable seizure management.
Partial-onset seizures Partial-onset seizures with or without secondary generalization Epilepsy requiring adjunctive or alternative antiepileptic therapy Patients intolerant or allergic to other antiepileptic drugs
As directed by the physician
Brivaracetam – 50 mg
Brivaracetam (50 mg) Binds to synaptic vesicle protein 2A (SV2A) with 15–30 times higher affinity than levetiracetam Enhances synaptic depression during epileptic activity Reduces excitatory neurotransmitter release Stabilizes abnormal neuronal firing Prevents seizure propagation and secondary generalization Exhibits high blood–brain barrier permeability for rapid onset of action Overall Effect: These actions lead to effective control of partial-onset seizures with improved onset, stability, and tolerability.
